Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics (NASDAQ:HRTX) in a research note published on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on HRTX. ValuEngine raised shares of Heron Therapeutics from a sell rating to a hold rating in a research note on Sunday, December 31st. Leerink Swann began coverage on shares of Heron Therapeutics in a research report on Tuesday, January 2nd. They set an outperform rating and a $22.00 price target for the company. Mizuho began coverage on shares of Heron Therapeutics in a research report on Tuesday, September 26th. They set a buy rating and a $28.00 price target for the company. BidaskClub raised shares of Heron Therapeutics from a sell rating to a hold rating in a research report on Wednesday, December 20th. Finally, Northland Securities began coverage on shares of Heron Therapeutics in a research report on Wednesday, September 27th. They set an outperform rating and a $40.00 price target for the company. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of Buy and an average price target of $28.82.

Shares of Heron Therapeutics (NASDAQ HRTX) remained flat at $$18.55 during trading on Friday. 594,400 shares of the company’s stock traded hands, compared to its average volume of 981,050. Heron Therapeutics has a fifty-two week low of $12.21 and a fifty-two week high of $19.55. The company has a market cap of $1,190.52, a PE ratio of -4.89 and a beta of 2.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The company had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. analysts anticipate that Heron Therapeutics will post -3.39 EPS for the current year.

Several large investors have recently bought and sold shares of HRTX. Schwab Charles Investment Management Inc. lifted its position in shares of Heron Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after purchasing an additional 1,026 shares during the period. Rhumbline Advisers lifted its position in shares of Heron Therapeutics by 14.1% in the 2nd quarter. Rhumbline Advisers now owns 50,630 shares of the biotechnology company’s stock worth $701,000 after purchasing an additional 6,249 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth about $457,000. Bank of New York Mellon Corp lifted its position in shares of Heron Therapeutics by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after purchasing an additional 14,086 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Heron Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the period. 98.78% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Reiterates “$31.00” Price Target for Heron Therapeutics (HRTX)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/08/cantor-fitzgerald-reiterates-31-00-price-target-for-heron-therapeutics-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related stocks with our FREE daily email newsletter.